Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Familial risk of colorectal cancer: the genes only tell part of the story

No. 42 | 26/09/2019 | by Rei

On the basis of a current epidemiological study, scientists at the German Cancer Research Center (DKFZ) conclude that the role of genes has been overestimated in patients with a higher familial risk of colorectal cancer. Other risk factors such as family dietary habits presumably have a greater impact that previously assumed. This will have implications for future calculations of individual risk and for the ensuing recommendations.

© Fotolia, yodiyim

Colorectal cancer is the third most common cancer in the world. Researchers currently assume that the disease is 35 percent hereditary. The main risk factors include a family history of the disease. In recent years, researchers have also identified around 100 tiny gene variations that are widespread in the population (single nucleotide polymorphisms - SNPs) and that affect the risk of colorectal cancer. However, current results obtained by the DKFZ scientists led by Hermann Brenner and Korbinian Weigl suggest that these SNPs account for a considerably lower share of the higher familial risk of colorectal cancer than previously assumed.

The DKFZ researchers began by examining the standard statistical methods used to estimate this share and noticed a number of weaknesses in the calculation which, when aggregated, lead to the impact of the SNPs being considerably overestimated. "In particular, the standard methods currently used assume that the familial clustering is ultimately 100 percent hereditary," noted Korbinian Weigl, lead author of the study. "On that basis, they then calculated the percentage that can be accounted for by the gene variants known to date."

The team led by Brenner and Weigl evaluated data on 7,927 subjects in a case control study, including 4,447 patients with colorectal cancer and 3,480 healthy subjects in the control group. "We developed a new method of calculation that does not assume right from the start that the familial risk is completely genetic in nature," explained study director Hermann Brenner. The researchers then used this method to evaluate the data on their probands.

The influence of the SNPs was indeed considerably lower using this method than assumed. While previous calculations estimated that the currently known gene variants account for 9.6 to 23.1 percent of the higher familial risk of colorectal cancer, the new calculations by the DKFZ researchers found an estimated influence of the SNPs of between 5.4 and 14.3 percent.

"The results correlate very well with the results of a different DKFZ study published last year," Brenner remarked. The previous study showed that in half-siblings of colorectal cancer patients, the risk of developing cancer was the same as for "real" siblings. "That suggests that common risk factors, such as particular dietary habits, smoking, or a lack of exercise, play a considerably greater role than previously assumed."

For the future assessment of the individual risk of colorectal cancer, that certainly does not mean that the gene variants associated with a heightened risk have become meaningless, however. "Instead, our study shows how important it is to look at both genetic and other risk factors in the family to arrive at a realistic assessment," Weigl continued. In other words, someone who only has a few risk-associated gene variants in their DNA should not rest assured that they will not develop colorectal cancer, for example if their lifestyle increases their risk. Conversely, colorectal cancer is not inevitable in people with an unfavorable genetic disposition if their individual behavior decreases their risk. At any rate, it is always advisable to make use of the very effective screening options for colorectal cancer.

Weigl K, Chang-Claude J, Hsu L, Hoffmeister M, Brenner H. Establishing a valid approach for estimating familial risk of cancer explained by common genetic variants. International Journal of Cancer 2019, DOI: 10.1002/ijc.32664

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.

RSS-Feed

Subscribe to our RSS-Feed.

to top
powered by webEdition CMS